Results 91 to 100 of about 31,379 (232)
, 2017 Amyloidosis is a disorder caused by misfolding of autologous protein and its extracellular deposition as fibrils, resulting in vital organ dysfunction and eventually death. Pulmonary amyloidosis may be localised or part of systemic amyloidosis. Pulmonary
Russo F. +5 more
core +2 more sources
Baillière's Clinical Rheumatology, 1994 Amyloidosis is a collective term for a heterogeneous group of disorders characterized by deposition of a fibrillar, proteinaceous material, amyloid, in various tissues and organs. Increasing knowledge about the different proteins that constitute the amyloid fibrils has made it possible to classify amyloidosis by the fibril protein, which appears more ...
openaire +3 more sources
A phenomap of TTR amyloidosis to aid diagnostic screening
ESC Heart Failure, Volume 12, Issue 2, Page 1113-1118, April 2025.Abstract Cardiac amyloidosis due to transthyretin (ATTR) remains an underdiagnosed cause of cardiomyopathy. As awareness of the disease grows and referrals for ATTR increase, clinicians are likely to encounter more atypical forms of the condition in clinical practice.
Alexios S. Antonopoulos +4 more
wiley +1 more source
, 2015 Amyloidosis is a disease characterised by accumulation of a fibrillar protein called amyloid in the extracellular space. The kidneys, ureters and the bladder can be affected in the urinary tract.
Hakan Türk +2 more
core +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1326-1335, April 2025.Abstract Aims Amyloid cardiomyopathy is caused by the deposition of light chain (AL) or transthyretin amyloid (ATTR) fibrils, that leads to a restrictive cardiomyopathy, often resulting in heart failure (HF) with preserved or reduced ejection fraction.
Robin Willixhofer +25 more
wiley +1 more source
Localized Secondary Amyloidosis of the Prostate
, 2014 Amyloidosis is an that is characterized the deposition of an abnormal proteinaceous material in extracellular tissue. Amyloidosis may be localized or systemic.
Nazım Emrah Koçer, Nebil Bal
core
Primary diffuse macular amyloidosis [PDF]
, 2015 We present a 53-year-old woman with diffuse macular amyloidosis. We discuss the clinical manifestations, pathophysiologic mechanisms, and associations of cutaneous macular ...
Shvartsbeyn, Marianna +12 more
core +1 more source
Amyloidosis and neurological disorders: Treatable amyloidosis
Rinsho Shinkeigaku, 2015 In neurological disorder related amyloidosis, several therapies have been developed in the recent decade. In AL and AA amyloidosis, novel chemotherapy and IL6 receptor antibody have been found to be effective, respectively. In addition to these amyloidosis, in transthyretin (TTR) related familial amyloidotic polyneuropathy (FAP), liver transplantation,
openaire +3 more sources
Effect of dialysis membrane and patient's age on signs of dialysis-related amyloidosis
, 1991 Effect of dialysis membrane and patient's age on signs of dialysis-related amyloidosis. This 12 center study was designed to assess factors affecting the development and progression of β2-microglobulin amyloidosis in long-term dialysis.
de Strihou, C. van Ypersele +5 more
core +1 more source
Update on treatment of light chain amyloidosis
Haematologica, 2014 Light chain amyloidosis is the most common type of amyloidosis as a consequence of protein misfolding of aggregates composed of amyloid fibrils. The clinical features are dependent on the organs involved, typically cardiac, renal, hepatic, peripheral and
Shameem Mahmood +3 more
doaj +1 more source